Current survival measures reliably reflect modern sequential
treatment in CML: Correlation with prognostic stratifications

J 2013

Current survival measures reliably reflect modern sequential treatment in CML: Correlation with prognostic stratifications

PAVLÍK, Tomáš, Eva JANOUŠOVÁ, Jiří MAYER, Karel INDRÁK, Marie JAROSOVA et. al.

Basic information

Original name

Current survival measures reliably reflect modern sequential treatment in CML: Correlation with prognostic stratifications

Authors

PAVLÍK, Tomáš (203 Czech Republic, guarantor, belonging to the institution), Eva JANOUŠOVÁ (203 Czech Republic, belonging to the institution), Jiří MAYER (203 Czech Republic, belonging to the institution), Karel INDRÁK (203 Czech Republic), Marie JAROSOVA (203 Czech Republic), Hana KLAMOVA (203 Czech Republic), Daniela ŽÁČKOVÁ (203 Czech Republic, belonging to the institution), Jaroslava VOGLOVÁ (203 Czech Republic), Edgar FABER (203 Czech Republic), Michal KARAS (203 Czech Republic), Katerina POLAKOVA MACHOVA (203 Czech Republic), Zdeněk RÁČIL (203 Czech Republic, belonging to the institution), Eva DEMEČKOVÁ (703 Slovakia), Ludmila DEMITROVIČOVÁ (703 Slovakia), Elena TOTHOVÁ (703 Slovakia), Juraj CHUDEJ (703 Slovakia), Imrich MARKULJAK (703 Slovakia), Eduard CMUNT (203 Czech Republic), Tomas KOZAK (203 Czech Republic), Jan MUŽÍK (203 Czech Republic, belonging to the institution) and Ladislav DUŠEK (203 Czech Republic, belonging to the institution)

Edition

American Journal of Hematology, Hoboken, Wiley-Blackwell, 2013, 0361-8609

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30200 3.2 Clinical medicine

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 3.477

RIV identification code

RIV/00216224:14110/13:00069543

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1002/ajh.23508

UT WoS

000323313500013

Keywords in English

CHRONIC MYELOID-LEUKEMIA; TYROSINE KINASE INHIBITORS; COMPLETE CYTOGENETIC RESPONSE; CHRONIC-PHASE; BCR-ABL; MOLECULAR RESPONSE; IMATINIB MESYLATE; INTERFERON-ALPHA; THERAPY; FAILURE

Abstract

V originále

Using the data of 723 chronic myeloid leukemia (CML) patients in the chronic phase, we analyzed the prognostic value of the Sokal, Euro, and EUTOS scores as well as the level of BCR-ABL1 and the achievement of complete cytogenetic response (CCgR) at 3 months of imatinib therapy in relation to the so-called current survival measures: the current cumulative incidence (CCI) reflecting the probability of being alive and in CCgR after starting imatinib therapy; the current leukemia-free survival (CLFS) reflecting the probability of being alive and in CCgR after achieving the first CCgR; and the overall survival. The greatest difference between the CCI curves at 5 years after initiating imatinib therapy was observed for the BCR-ABL1 transcripts at 3 months. The 5-year CCI was 94.3% in patients with BCR-ABL1 transcripts10% and 57.1% in patients with BCR-ABL1 transcripts>10% (P=0.005). Therefore, the examination of BCR-ABL1 transcripts at 3 months may help in early identification of patients who are likely to perform poorly with imatinib. On the other hand, CLFS was not significantly affected by the considered stratifications. In conclusion, our results indicate that once the CCgR is achieved, the prognosis is good irrespective of the starting prognostic risks.

Citovat

PAVLÍK, Tomáš, Eva JANOUŠOVÁ, Jiří MAYER, Karel INDRÁK, Marie JAROSOVA, Hana KLAMOVA, Daniela ŽÁČKOVÁ, Jaroslava VOGLOVÁ, Edgar FABER, Michal KARAS, Katerina POLAKOVA MACHOVA, Zdeněk RÁČIL, Eva DEMEČKOVÁ, Ludmila DEMITROVIČOVÁ, Elena TOTHOVÁ, Juraj CHUDEJ, Imrich MARKULJAK, Eduard CMUNT, Tomas KOZAK, Jan MUŽÍK and Ladislav DUŠEK. Current survival measures reliably reflect modern sequential treatment in CML: Correlation with prognostic stratifications. American Journal of Hematology. Hoboken: Wiley-Blackwell, 2013, vol. 88, No 9, p. 790-797. ISSN 0361-8609. Available from: https://dx.doi.org/10.1002/ajh.23508.

@article{1124313,
   author = {Pavlík, Tomáš and Janoušová, Eva and Mayer, Jiří and Indrák, Karel and Jarosova, Marie and Klamova, Hana and Žáčková, Daniela and Voglová, Jaroslava and Faber, Edgar and Karas, Michal and Polakova Machova, Katerina and Ráčil, Zdeněk and Demečková, Eva and Demitrovičová, Ludmila and Tothová, Elena and Chudej, Juraj and Markuljak, Imrich and Cmunt, Eduard and Kozak, Tomas and Mužík, Jan and Dušek, Ladislav},
   article_location = {Hoboken},
   article_number = {9},
   doi = {http://dx.doi.org/10.1002/ajh.23508},
   keywords = {CHRONIC MYELOID-LEUKEMIA; TYROSINE KINASE INHIBITORS; COMPLETE CYTOGENETIC RESPONSE; CHRONIC-PHASE; BCR-ABL; MOLECULAR RESPONSE; IMATINIB MESYLATE; INTERFERON-ALPHA; THERAPY; FAILURE},
   language = {eng},
   issn = {0361-8609},
   journal = {American Journal of Hematology},
   title = {Current survival measures reliably reflect modern sequential treatment in CML: Correlation with prognostic stratifications},
   volume = {88},
   year = {2013}
}

TY  - JOUR
ID  - 1124313
AU  - Pavlík, Tomáš - Janoušová, Eva - Mayer, Jiří - Indrák, Karel - Jarosova, Marie - Klamova, Hana - Žáčková, Daniela - Voglová, Jaroslava - Faber, Edgar - Karas, Michal - Polakova Machova, Katerina - Ráčil, Zdeněk - Demečková, Eva - Demitrovičová, Ludmila - Tothová, Elena - Chudej, Juraj - Markuljak, Imrich - Cmunt, Eduard - Kozak, Tomas - Mužík, Jan - Dušek, Ladislav
PY  - 2013
TI  - Current survival measures reliably reflect modern sequential treatment in CML: Correlation with prognostic stratifications
JF  - American Journal of Hematology
VL  - 88
IS  - 9
SP  - 790-797
EP  - 790-797
PB  - Wiley-Blackwell
SN  - 03618609
KW  - CHRONIC MYELOID-LEUKEMIA
KW  - TYROSINE KINASE INHIBITORS
KW  - COMPLETE CYTOGENETIC RESPONSE
KW  - CHRONIC-PHASE
KW  - BCR-ABL
KW  - MOLECULAR RESPONSE
KW  - IMATINIB MESYLATE
KW  - INTERFERON-ALPHA
KW  - THERAPY
KW  - FAILURE
N2  - Using the data of 723 chronic myeloid leukemia (CML) patients in the chronic phase, we analyzed the prognostic value of the Sokal, Euro, and EUTOS scores as well as the level of BCR-ABL1 and the achievement of complete cytogenetic response (CCgR) at 3 months of imatinib therapy in relation to the so-called current survival measures: the current cumulative incidence (CCI) reflecting the probability of being alive and in CCgR after starting imatinib therapy; the current leukemia-free survival (CLFS) reflecting the probability of being alive and in CCgR after achieving the first CCgR; and the overall survival. The greatest difference between the CCI curves at 5 years after initiating imatinib therapy was observed for the BCR-ABL1 transcripts at 3 months. The 5-year CCI was 94.3% in patients with BCR-ABL1 transcripts10% and 57.1% in patients with BCR-ABL1 transcripts>10% (P=0.005). Therefore, the examination of BCR-ABL1 transcripts at 3 months may help in early identification of patients who are likely to perform poorly with imatinib. On the other hand, CLFS was not significantly affected by the considered stratifications. In conclusion, our results indicate that once the CCgR is achieved, the prognosis is good irrespective of the starting prognostic risks.
ER  -

PAVLÍK, Tomáš, Eva JANOUŠOVÁ, Jiří MAYER, Karel INDRÁK, Marie JAROSOVA, Hana KLAMOVA, Daniela ŽÁČKOVÁ, Jaroslava VOGLOVÁ, Edgar FABER, Michal KARAS, Katerina POLAKOVA MACHOVA, Zdeněk RÁČIL, Eva DEMEČKOVÁ, Ludmila DEMITROVIČOVÁ, Elena TOTHOVÁ, Juraj CHUDEJ, Imrich MARKULJAK, Eduard CMUNT, Tomas KOZAK, Jan MUŽÍK and Ladislav DUŠEK. Current survival measures reliably reflect modern sequential treatment in CML: Correlation with prognostic stratifications. \textit{American Journal of Hematology}. Hoboken: Wiley-Blackwell, 2013, vol.~88, No~9, p.~790-797. ISSN~0361-8609. Available from: https://dx.doi.org/10.1002/ajh.23508.

Detailed Information on Publication Record